These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37154625)

  • 21. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Khanna D; Hays RD; Maranian P; Seibold JR; Impens A; Mayes MD; Clements PJ; Getzug T; Fathi N; Bechtel A; Furst DE
    Arthritis Rheum; 2009 Sep; 61(9):1257-63. PubMed ID: 19714600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts.
    Volkmann ER; Hoffmann-Vold AM; Chang YL; Jacobs JP; Tillisch K; Mayer EA; Clements PJ; Hov JR; Kummen M; Midtvedt Ø; Lagishetty V; Chang L; Labus JS; Molberg Ø; Braun J
    BMJ Open Gastroenterol; 2017; 4(1):e000134. PubMed ID: 28761687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive relationships between gut microbiome and faecal metabolome in individuals with type 2 diabetes and its complications.
    Zhao L; Lou H; Peng Y; Chen S; Zhang Y; Li X
    Endocrine; 2019 Dec; 66(3):526-537. PubMed ID: 31591683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement.
    Mitri GM; Lucas M; Fertig N; Steen VD; Medsger TA
    Arthritis Rheum; 2003 Jan; 48(1):203-9. PubMed ID: 12528120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of high intake of cod or salmon on gut microbiota profile, faecal output and serum concentrations of lipids and bile acids in overweight adults: a randomised clinical trial.
    Bratlie M; Hagen IV; Helland A; Erchinger F; Midttun Ø; Ueland PM; Rosenlund G; Sveier H; Mellgren G; Hausken T; Gudbrandsen OA
    Eur J Nutr; 2021 Jun; 60(4):2231-2248. PubMed ID: 33108521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis.
    Gualtierotti R; Ingegnoli F; Two R; Meroni PL; Khanna D; Adorni G; Becciolini A; Ciavarella T; Marfia G; Murgo A; Scalone L; Ughi N; Zeni S;
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S55-60. PubMed ID: 26339890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Autoantibodies in systemic sclerosis and their clinical correlation in patients from a Midwestern region of Brazil].
    Coelho Horimoto AM; da Costa IP
    Rev Bras Reumatol; 2015; 55(3):229-39. PubMed ID: 25559063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
    Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
    Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Bae S; Allanore Y; Coustet B; Maranian P; Khanna D
    Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S15-21. PubMed ID: 21586213
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis.
    Baron M; Hudson M; Steele R; Lo E;
    J Rheumatol; 2011 Sep; 38(9):1925-30. PubMed ID: 21724704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis.
    Raschi E; Privitera D; Bodio C; Lonati PA; Borghi MO; Ingegnoli F; Meroni PL; Chighizola CB
    Arthritis Res Ther; 2020 Nov; 22(1):265. PubMed ID: 33168071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastrointestinal symptom severity and progression in systemic sclerosis.
    van Leeuwen NM; Boonstra M; Fretheim H; Brunborg C; Midtvedt Ø; Garen T; Molberg Ø; Huizinga TWJ; de Vries-Bouwstra JK; Hoffman-Vold AM
    Rheumatology (Oxford); 2022 Oct; 61(10):4024-4034. PubMed ID: 35238377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prebiotic administration modulates gut microbiota and faecal short-chain fatty acid concentrations but does not prevent chronic intermittent hypoxia-induced apnoea and hypertension in adult rats.
    O'Connor KM; Lucking EF; Bastiaanssen TFS; Peterson VL; Crispie F; Cotter PD; Clarke G; Cryan JF; O'Halloran KD
    EBioMedicine; 2020 Sep; 59():102968. PubMed ID: 32861200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind randomized placebo-controlled trial of probiotics in systemic sclerosis associated gastrointestinal disease.
    Low AHL; Teng GG; Pettersson S; de Sessions PF; Ho EXP; Fan Q; Chu CW; Law AHN; Santosa A; Lim AYN; Wang YT; Haaland B; Thumboo J
    Semin Arthritis Rheum; 2019 Dec; 49(3):411-419. PubMed ID: 31208714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Symptoms related to gastrointestinal tract involvement and low muscularity in systemic sclerosis.
    Rosato E; Gigante A; Pellicano C; Villa A; Iannazzo F; Alunni Fegatelli D; Muscaritoli M
    Clin Rheumatol; 2022 Jun; 41(6):1687-1696. PubMed ID: 35149929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis.
    Ahmed F; Maclean RH; Nihtyanova SI; Ong VH; Murray CD; Denton CP
    Rheumatology (Oxford); 2022 Feb; 61(2):781-786. PubMed ID: 33909895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gut microbiota and short-chain fatty acid alterations in cachectic cancer patients.
    Ubachs J; Ziemons J; Soons Z; Aarnoutse R; van Dijk DPJ; Penders J; van Helvoort A; Smidt ML; Kruitwagen RFPM; Baade-Corpelijn L; Olde Damink SWM; Rensen SS
    J Cachexia Sarcopenia Muscle; 2021 Dec; 12(6):2007-2021. PubMed ID: 34609073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations.
    Gourh P; Arnett FC; Assassi S; Tan FK; Huang M; Diekman L; Mayes MD; Reveille JD; Agarwal SK
    Arthritis Res Ther; 2009; 11(5):R147. PubMed ID: 19799786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical associations of anti-CENP-B and anti-Scl70 antibody levels measured by multiplexed fluorescent microsphere immunoassay in systemic sclerosis.
    Volpe A; Ruzzenente O; Caramaschi P; Pieropan S; Tinazzi I; Carletto A; Bambara LM; Biasi D
    Rheumatol Int; 2009 Jul; 29(9):1073-9. PubMed ID: 19194705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.